

1S Advancing Global Nuclear Medicine: The Role and Future Contributions of China

Haojun Chen, Kuangyu Shi, Weibo Cai, Sijin Li, and Jing Wang

Chen and colleagues introduce this *JNM* supplement, a timely overview of the current status of nuclear medicine in China, highlighting significant advances in research and development, as well as clinical translation of novel radiopharmaceuticals.

4S Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China

Liang Zhao, Fei Kang, Yizhen Pang, Jianyang Fang, Long Sun, Hua Wu, XiaoLi Lan, Jing Wang, and Haojun Chen

Zhao and colleagues offer an in-depth review of the evolution and use of FAP tracers in China, from preclinical to clinical research, including the expanding potential of FAP-targeted radionuclide therapy.

12S Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with ⁶⁸Ga-N188

Jianhua Zhang, Xiaojiang Duan, Xueqi Chen, Zhuochen Zhang, Hongwei Sun, Jiayin Shou, Guangyu Zhao, Jianxin Wang, Yongsu Ma, Yinmo Yang, et al.

Zhang and colleagues report on the feasibility of nectin-4–targeted PET imaging as a noninvasive method to quantify membranous nectin-4 expression in various tumor types—an approach with promise for patient stratification and treatment selection.

19S Melanin-Targeting Radiotracers and Their Preclinical, Translational, and Clinical Status: From Past to Future

Xiao Zhang, Zhaoguo Lin, Yuan Feng, Fei Kang, Jing Wang, and Xiaoli Lan

Zhang and colleagues describe the features of melanin-targeted radiolabeled molecules as detailed in preclinical studies, clinical trials, and patient practice, with additional discussion of novel applications.

29S Landscape of Nuclear Medicine in China and Its Progress on Theranostics

Weidong Yang, Fei Kang, Yue Chen, Zhaohui Zhu, Feng Wang, Chunxia Qin, Jin Du, Xiaoli Lan, and Jing Wang

Yang and colleagues review historic milestones and current status of nuclear medicine in China, including radioisotope production, radiopharmaceutical development, advanced instrumentation, and theranostic research.

38S Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview

Jingming Zhang, Fei Kang, Xiao Wang, Xuejiao Chen, Xing Yang, Zhi Yang, and Jing Wang

Zhang and colleagues review the exploration of novel imaging targets, preclinical evaluation of targeting ligands, and associated translational research in China from 2020 to 2023.

46S The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook

Xiangxi Meng, Xiangxing Kong, Lei Xia, Runze Wu, Hua Zhu, and Zhi Yang

Meng and colleagues look at advances in total-body PET imaging and the impact of its introduction on drug development, novel tracers, and new clinical opportunities.

54S Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer Center

Wanqi Chen, Yinghe Li, Zhijian Li, Yongluo Jiang, Yingpu Cui, Jiling Zeng, Yiwen Mo, Si Tang, Shatong Li, Lei Liu, et al.

Chen and colleagues document clinical experience with total-body PET at their institution, including diseases treated, patient selection, workflow, scanning protocols, and enhanced applications.

64S Clinical Implementation of Total-Body PET in China

Yaping Wu, Tao Sun, Yee Ling Ng, Jianjun Liu, Xiaohua Zhu, Zhaoping Cheng, Baixuan Xu, Nan Meng, Yun Zhou, and Meiyun Wang

Wu and colleagues assess the use of total-body PET in China for both oncologic and nononcologic indications, highlighting recent technologic innovations and challenges to widespread clinical integration.

72S Pathway to Approval of Innovative Radiopharmaceuticals in China

Shuxian An, Lu Wang, Fang Xie, Dawei Jiang, Gang Huang, Jianjun Liu, Xiaowei Ma, Weijun Wei

An and colleagues provide an overview of the approval process for novel radiopharmaceuticals by China's National Medical Products Administration and the status of radiolabeled agents in research and development.

GUEST EDITORS

Wolfgang Weber, MD, PhD
Technical University of Munich
Munich, Germany

Ken Herrmann, MD, MBA
Universitätsklinikum Essen
Essen, Germany

Haojun Chen, MD, PhD
The First Affiliated Hospital of Xiamen University
Xiamen, China

Kuangyu Shi, PhD
University of Bern
Bern, Switzerland

Weibo Cai, PhD
University of Wisconsin
Madison, Wisconsin

Editor-in-Chief

Johannes Czernin, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

Opinions expressed in the contributions to this supplement are solely those of the authors and do not necessarily reflect those of *The Journal of Nuclear Medicine* or the Society of Nuclear Medicine and Molecular Imaging. The journal, however, invites and welcomes different opinions in order to initiate and stimulate discussion.